论文部分内容阅读
目的 Tocomparetheprogression-freesurvival(PFS)ofChinesepatientswithALK-positive,advancedlungadenocarcinomawhoreceivedfirst-linecrizotinibtherapywiththatofpatientswhoreceivedfirst-linestandardchemotherapy,andalsothePFSbenefitoffirst-lineversussecond-linecrizotinibtreatment.